LY-411575_209984-57-6_CoA_MedChemExpress
高效液相色谱内标法测定鸡蛋中氯羟吡啶的残留量
图 １ 氯 羟 毗 喔 的 化 学 结 构
氯 羟吡 啶 ， 名 克 球 酚 ， 学 名 为 ３ ５－ 氯一 ， 又 化 ，－ ２ ６二 甲基 一一 一 ４羟基 吡 啶 （ １ ， 一 种 广 谱 抗 球 虫增 图 ）是
效剂 ， 主要 用 于预 防和 治疗 畜禽 的球 虫病 ， 畜禽 饲 在
氯 羟 吡 啶标 准 溶 液 ： 确称 取 氯 羟 吡啶 标 准 品 准
１５ －１ ．ｅ
１Ｏ 一１ ．ｅ
２
５Ｏ 一 ．ｅ ２ ０Ｏ
２ ０ ６０ １ ０ １ ．０ ｌ Ｌ ．０ ．０ ０．０ ４ ０ ．Ｕ ）
０ ０ ０ ， 内标 溶 液 溶 解 并 稀 释 至 １ ０ｍＬ， ． １０ｇ 用 ０ 制成 浓 度 为 １ ０／ ｍＬ １ ０ ｚ ｇ・ Ⅲ 的标 准储 备液 （ 内标物 ） 含 。 标 准工 作液 ： 适量 的氯 羟吡 啶标准 储备 液 ， 取 用
准 ， 中又 以我 国 和 日本 的规 定 最 为严 格 。我 国政 其 府 规 定 氯 羟 吡 啶 在 鸡 肉 中 的 残 留 量 为 ５ ｇ・ Ｏ
ｋｇ一 ［ 。 引
目前 ， 氯羟 吡 啶的残 留检测 方法 主要有 ： 薄层 色
谱 法 、 相 色谱 法 （ Ｃ）５、 相 色谱 一质 谱 联 用 ］气 Ｇ ［ 气 ３ 法 （ ＭＳ ］ 高效 液相 色 谱 法 （ Ｌ ）９１ 、 ＧＣ ） 、 ＨＰ Ｃ ［ ３ 高 －］ 效 液相 色谱 一质 谱联 用 法 （ Ｌ － ）１ ＨＰ Ｃ ＭＳ ＿ 。气 相 色 谱 通常 需要衍 生 化处 理 ， 对繁 杂 ； 相 薄层色谱 法分 析 时间长 ， 不便 于定 量 ； 也 高效 液 相 色 谱法 具 有 简 便 、
均 为分析 纯 ； 水为 Ｍｉｉｏ ｅ ｌｐ ｒ 超纯 水 。 ｌ
MetaPolyzyme DNA free 产品说明书
MAC4LDFpis Rev 04/221Product InformationMetaPolyzyme, DNA freeSuitable for Microbiome researchMAC4LDFSynonym: Multilytic Enzyme Mix Storage Temperature –20 °CProduct DescriptionMetagenomics investigates all DNA that has been isolated directly from given single samples, such as environmental samples or biological organisms.1,2Metagenomics allows for the investigation of microbes that exist in extreme environments, and which have been historically difficult to isolate, culture, andstudy.3 Metagenomics has revealed the existence of novel microbial species.4 Applications ofmetagenomics work include public health dataanalysis,5,6 discovery of novel proteins, enzymes and natural products,7,8 environmental studies,9,10 and agricultural investigations.11,12Microbes are difficult to disrupt because the cell walls may form capsules or resistant spores. DNA can be extracted by using lysing enzymes such as lyticase, chitinase, zymolase, and gluculase to induce partial spheroplast formation. Spheroplasts are subsequently lysed to release DNA.MetaPolyzyme products (Cat. Nos. MAC4L, MAC4LDF) are based on a multi-lytic enzyme mixture, originally developed by Scott Tighe, for use in microbiome and DNA extraction efficiency studies, and formulated for effective lysis of microbiome samples from extreme environments. MetaPolyzyme was originally evaluated and developed in consultation and collaboration with the Association of Biomolecular Resource Facilities (ABRF) Metagenomics and Microbiome ResearchGroup (MMRG; formerly the Metagenomics Research Group, MGRG).13-16Studies of microbial communities have beenenhanced by the use of culture-independent analytical techniques such as 16S rRNA gene sequencing and metagenomics. DNA contamination during sample preparation is a major problem of sequence-based approaches. Extraction reagents free of DNA contaminants are thus essential. MetaPolyzyme, DNA free was developed to address the need for DNA-free reagents, to minimize microbial DNA contamination from reagents. This productundergoes strict quality control testing to ensure the absence of detectable levels of contaminatingmicrobial DNA using 35 cycles PCR amplification of 16S and 18S rDNA using universal primer sets.Precautions and DisclaimerFor R&D use only. Not for drug, household, or other uses. Please consult the Safety Data Sheet for information regarding hazards and safe handling practices.ReagentThe enzymes in MetaPolyzyme, DNA free are:• Mutanolysin • Achromopeptidase • Lyticase • Chitinase • Lysostaphin •LysozymeAll the enzymes are individually tested for theabsence of contaminating DNA using 16S and 18S PCR amplification.Mutanolysin (from Streptomyces globisporus )Mutanolysin is a muralytic enzyme (muramidase) that cleaves the β-N -acetylmuramyl-(1→4)-N -acetylglucosamine linkage of the bacterial cell wall peptidoglycan-polysaccharide, particularly the β(1→4) bond in MurNAc-GlcNAc.17 Mutanolysin particularly acts on many Gram-positive bacteria, where the enzyme’s carboxy -terminal moietiesparticipate in the recognition and binding of unique cell wall structures.MAC4LDFpis Rev 04/22AchromopeptidaseAchromopeptidase (known also as β-lytic protease 18) has potent bacteriolytic activity on many Gram-positive aerobic bacteria 19 with high lytic activity, against bacterial strains with the A1α chemotype (such as Aerococcus viridans ), and the A3αchemotype (such as Staphylococcus epidermidis ) for cell wall peptidoglycan structures. The enzyme has been reported to have particular recognition for Gly-X sites in peptide sequences, and for Gly-Gly and ᴅ-Ala-X sites in peptidoglycans.20Lyticase (from Arthrobacter luteus )Lyticase is useful in digestion of linear glucosepolymers with β(1→3) linkages, of yeast glycan coats and for spheroplast formation, and of the cell wall of active yeast cells.Chitinase (from Streptomyces griseus )Chitinase degrades chitin by enzymatic hydrolysis to N-acetyl-D-glucosamine. Degradation occurs via two consecutive enzyme reactions: •Chitodextrinase-chitinase, apoly(1,4-β-[2-acetamido-2-deoxy-D-glucoside])-glycanohydrolase, removes chitobiose units from chitin.•N-acetylglucosaminidase-chitobiase cleaves the disaccharide to its monomer subunits, N-acetyl-D-glucosamine (NAGA).Lysostaphin (from Staphylococcus staphylolyticus )Lysostaphin is a lytic enzyme with activity against Staphylococcus species, including S. aureus . Lysostaphin has hexosaminidase, amidase, and endopeptidase activities. It cleaves polyglycine crosslinks in the cellular wall of Staphylococcus species, which leads to cell lysis.21,22Lysozyme (from chicken egg white)Lysozyme hydrolyzes β(1→4) linkages betweenN -acetylmuraminic acid and N -acetyl-D-glucosamine residues in peptidoglycan, and betweenN -acetyl-D-glucosamine residues in chitodextrin. Lysozyme lyses the peptidoglycan cell wall of Gram-positive bacteria.23Storage/StabilityThis product ships at cooler temperature conditions. Long-term storage at –20 °C is recommended. Reconstituted solutions of MetaPolyzyme, DNA free may be stored at –20 °C, but long-term solution stability has not been examined.Preparation InstructionsBecause of the great diversity of samples formetagenomics studies, it will be necessary for each researcher to work out particular conditions for optimal sample preparation and treatment. It is recommended to reconstitute MetaPolyzyme, DNA free in sterile PBS buffer, pH 7.5 (no EDTA, calcium or magnesium present in solution). The following is a sample procedure, to be scaled appropriately:1. Add 100 µL of sterile PBS (pH 7.5) to 1 vial ofMetaPolyzyme, DNA free.1.1. Resuspend by gentle agitation or pipetting. 1.2. Set solution aside at 2-8 °C until Step 7. 2. Thoroughly suspend sample in sterile PBS(pH 7.5). 3. Add 200 µL of sample in PBS to a 2 mLpolypropylene microcentrifuge tube. 4. Optional pellet wash:4.1. To sample tube, add 1 mL of PBS (pH 7.5). 4.2. Vortex, centrifuge and remove supernatant. 4.3. Repeat pellet wash two more times ifneeded. 5. Resuspend pelleted sample in 150 µL of PBS(pH 7.5). Vortex thoroughly.6. Optional: if solution will sit for more than 4 hours,sodium azide may be added to 0.02%. 7. Add 20 µL (*) of MetaPolyzyme, DNA free tosample solution. 8. Incubate at 35 °C for 2-24 hours.9. Continue with standard DNA extraction protocol. (*) The optimal volume and concentration of MetaPolyzyme, DNA free may vary in different experiments.References1. Gilbert, J.A., and Dupont, C.L., Ann. Rev. MarineSci., 3, 347-371 (2011). 2. Kang, H.S., and Brady, S.F., J. Am. Chem. Soc.,136(52), 18111-18119 (2014). 3. Ufarté, L. et al., Biotechnol. Adv., 33(8),1845-1854 (2015). 4. Davison, M. et al., Photosynth. Res., 126(1),135-146 (2015). 5. Afshinnekoo, E. et al., Cell Syst., 1(1), 72-87(2015).The life science business of Merck operatesas MilliporeSigma in the U.S. and Canada.Merck and Sigma-Aldrich are trademarks of Merck KGaA, Darmstadt, Germany or its affiliates.All other trademarks are the property of their respective owners. Detailed information on trademarks is available via publicly accessible resources.© 2022 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.MAC4LDFpis Rev 04/22 DK,DT,GCY,TJ,RBG,SBC,MAM36.The MetaSUB International Consortium,Microbiome, 4, 24 (2016). [Erratum inMicrobiome, 4, 45 (2016).]7.Trinidade, M. et al., Front. Microbiol., 6, 890(2015).8.Coughlan, L.M. et al., Front. Microbiol., 6, 672(2015).9.Palomo, A. et al., ISME J., 10(11), 2569-2581(2016).10.Pold, G. et al., Appl. Environ. Microbiol., 82(22),6518-6530 (2016).11.Mitra, N. et al., J. Gen. Virol., 97(8), 1771-1784(2016).12.Theuns, S. et al., Infect. Genet. Evol., 43,135-145 (2016).13.Baldwin, D.A. et al., "Life at the Extreme", ABRFMetagenomics Research Group Poster 2015,presented at the ABRF 2015 Conference, St.Louis, MO, USA, March 28-31, 2015.14.Baldwin, D.A. et al., "Implementing NewStandards in Metagenomics and the ExtremeMicrobiome Project", ABRF MetagenomicsResearch Group Poster 2016, presented at theABRF 2016 Conference, Fort Lauderdale, FL, USA, February 20-23, 2016.15.McIntyre, A. et al., "Life at the Extreme: TheABRF Metagenomics Research Group", ABRFMetagenomics Research Group Poster 2017,presented at the ABRF 2017 Conference, SanDiego, CA, March 25-28, 2017.16.Tighe, S. et al., J. Biomol. Tech., 28(1), 31-39(2017).17.Gründling, A., and Schneewind, O., J. Bacteriol.,188(7), 2463-2472 (2006).18.Li, S.L. et al., J. Bacteriol., 172(11), 6506-6511(1990).19.Ezaki, T., and Suzuki, S., J. Clin. Microbiol.,16(5), 844-846 (1982). 20.Li, S. et al., J. Biochem., 124(2), 332-339(1998).21.Browder, H.P. et al., Biochem. Biophys. Res.Commun., 19, 383-389 (1965).22.Robinson, J.M. et al., J. Bacteriol., 137(3),1158-1164 (1979).23.Vocaldo, D.J. et al., Nature, 412(6849), 835-838(2001).NoticeWe provide information and advice to our customers on application technologies and regulatory matters to the best of our knowledge and ability, but without obligation or liability. Existing laws and regulations are to be observed in all cases by our customers. This also applies in respect to any rights of third parties. Our information and advice do not relieve our customers of their own responsibility for checking the suitability of our products for the envisaged purpose. The information in this document is subject to change without notice and should not be construed as a commitment by the manufacturing or selling entity, or an affiliate. We assume no responsibility for any errors that may appear in this document.Technical AssistanceVisit the tech service page at/techservice.Standard WarrantyThe applicable warranty for the products listed in this publication may be found at /terms. Contact InformationFor the location of the office nearest you, go to /offices.。
EL-102_SDS_MedChemExpress
Inhibitors, Agonists, Screening LibrariesSafety Data Sheet Revision Date:May-24-2017Print Date:May-24-20171. PRODUCT AND COMPANY IDENTIFICATION1.1 Product identifierProduct name :EL-102Catalog No. :HY-16187CAS No. :1233948-61-21.2 Relevant identified uses of the substance or mixture and uses advised againstIdentified uses :Laboratory chemicals, manufacture of substances.1.3 Details of the supplier of the safety data sheetCompany:MedChemExpress USATel:609-228-6898Fax:609-228-5909E-mail:sales@1.4 Emergency telephone numberEmergency Phone #:609-228-68982. HAZARDS IDENTIFICATION2.1 Classification of the substance or mixtureNot a hazardous substance or mixture.2.2 GHS Label elements, including precautionary statementsNot a hazardous substance or mixture.2.3 Other hazardsNone.3. COMPOSITION/INFORMATION ON INGREDIENTS3.1 SubstancesSynonyms:EL 102; EL102Formula:C19H16N2O3S2Molecular Weight:384.47CAS No. :1233948-61-24. FIRST AID MEASURES4.1 Description of first aid measuresEye contactRemove any contact lenses, locate eye-wash station, and flush eyes immediately with large amounts of water. Separate eyelids with fingers to ensure adequate flushing. Promptly call a physician.Skin contactRinse skin thoroughly with large amounts of water. Remove contaminated clothing and shoes and call a physician.InhalationImmediately relocate self or casualty to fresh air. If breathing is difficult, give cardiopulmonary resuscitation (CPR). Avoid mouth-to-mouth resuscitation.IngestionWash out mouth with water; Do NOT induce vomiting; call a physician.4.2 Most important symptoms and effects, both acute and delayedThe most important known symptoms and effects are described in the labelling (see section 2.2).4.3 Indication of any immediate medical attention and special treatment neededTreat symptomatically.5. FIRE FIGHTING MEASURES5.1 Extinguishing mediaSuitable extinguishing mediaUse water spray, dry chemical, foam, and carbon dioxide fire extinguisher.5.2 Special hazards arising from the substance or mixtureDuring combustion, may emit irritant fumes.5.3 Advice for firefightersWear self-contained breathing apparatus and protective clothing.6. ACCIDENTAL RELEASE MEASURES6.1 Personal precautions, protective equipment and emergency proceduresUse full personal protective equipment. Avoid breathing vapors, mist, dust or gas. Ensure adequate ventilation. Evacuate personnel to safe areas.Refer to protective measures listed in sections 8.6.2 Environmental precautionsTry to prevent further leakage or spillage. Keep the product away from drains or water courses.6.3 Methods and materials for containment and cleaning upAbsorb solutions with finely-powdered liquid-binding material (diatomite, universal binders); Decontaminate surfaces and equipment by scrubbing with alcohol; Dispose of contaminated material according to Section 13.7. HANDLING AND STORAGE7.1 Precautions for safe handlingAvoid inhalation, contact with eyes and skin. Avoid dust and aerosol formation. Use only in areas with appropriate exhaust ventilation.7.2 Conditions for safe storage, including any incompatibilitiesKeep container tightly sealed in cool, well-ventilated area. Keep away from direct sunlight and sources of ignition.Recommended storage temperature:Powder-20°C 3 years4°C 2 yearsIn solvent-80°C 6 months-20°C 1 monthShipping at room temperature if less than 2 weeks.7.3 Specific end use(s)No data available.8. EXPOSURE CONTROLS/PERSONAL PROTECTION8.1 Control parametersComponents with workplace control parametersThis product contains no substances with occupational exposure limit values.8.2 Exposure controlsEngineering controlsEnsure adequate ventilation. Provide accessible safety shower and eye wash station.Personal protective equipmentEye protection Safety goggles with side-shields.Hand protection Protective gloves.Skin and body protection Impervious clothing.Respiratory protection Suitable respirator.Environmental exposure controls Keep the product away from drains, water courses or the soil. Cleanspillages in a safe way as soon as possible.9. PHYSICAL AND CHEMICAL PROPERTIES9.1 Information on basic physical and chemical propertiesAppearance Light yellow to yellow (Solid)Odor No data availableOdor threshold No data availablepH No data availableMelting/freezing point No data availableBoiling point/range No data availableFlash point No data availableEvaporation rate No data availableFlammability (solid, gas)No data availableUpper/lower flammability or explosive limits No data availableVapor pressure No data availableVapor density No data availableRelative density No data availableWater Solubility No data availablePartition coefficient No data availableAuto-ignition temperature No data availableDecomposition temperature No data availableViscosity No data availableExplosive properties No data availableOxidizing properties No data available9.2 Other safety informationNo data available.10. STABILITY AND REACTIVITY10.1 ReactivityNo data available.10.2 Chemical stabilityStable under recommended storage conditions.10.3 Possibility of hazardous reactionsNo data available.10.4 Conditions to avoidNo data available.10.5 Incompatible materialsStrong acids/alkalis, strong oxidising/reducing agents.10.6 Hazardous decomposition productsUnder fire conditions, may decompose and emit toxic fumes.Other decomposition products - no data available.11.TOXICOLOGICAL INFORMATION11.1 Information on toxicological effectsAcute toxicityClassified based on available data. For more details, see section 2Skin corrosion/irritationClassified based on available data. For more details, see section 2Serious eye damage/irritationClassified based on available data. For more details, see section 2Respiratory or skin sensitizationClassified based on available data. For more details, see section 2Germ cell mutagenicityClassified based on available data. For more details, see section 2CarcinogenicityIARC: No component of this product present at a level equal to or greater than 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.ACGIH: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by ACGIH.NTP: No component of this product present at a level equal to or greater than 0.1% is identified as a anticipated or confirmed carcinogen by NTP.OSHA: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by OSHA.Reproductive toxicityClassified based on available data. For more details, see section 2Specific target organ toxicity - single exposureClassified based on available data. For more details, see section 2Specific target organ toxicity - repeated exposureClassified based on available data. For more details, see section 2Aspiration hazardClassified based on available data. For more details, see section 212. ECOLOGICAL INFORMATION12.1 ToxicityNo data available.12.2 Persistence and degradabilityNo data available.12.3 Bioaccumlative potentialNo data available.12.4 Mobility in soilNo data available.12.5 Results of PBT and vPvB assessmentPBT/vPvB assessment unavailable as chemical safety assessment not required or not conducted.12.6 Other adverse effectsNo data available.13. DISPOSAL CONSIDERATIONS13.1 Waste treatment methodsProductDispose substance in accordance with prevailing country, federal, state and local regulations.Contaminated packagingConduct recycling or disposal in accordance with prevailing country, federal, state and local regulations.14. TRANSPORT INFORMATIONDOT (US)This substance is considered to be non-hazardous for transport.IMDGThis substance is considered to be non-hazardous for transport.IATAThis substance is considered to be non-hazardous for transport.15. REGULATORY INFORMATIONSARA 302 Components:No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.SARA 313 Components:This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.SARA 311/312 Hazards:No SARA Hazards.Massachusetts Right To Know Components:No components are subject to the Massachusetts Right to Know Act.Pennsylvania Right To Know Components:No components are subject to the Pennsylvania Right to Know Act.New Jersey Right To Know Components:No components are subject to the New Jersey Right to Know Act.California Prop. 65 Components:This product does not contain any chemicals known to State of California to cause cancer, birth defects, or anyother reproductive harm.16. OTHER INFORMATIONCopyright 2017 MedChemExpress. The above information is correct to the best of our present knowledge but does not purport to be all inclusive and should be used only as a guide. The product is for research use only and for experienced personnel. It must only be handled by suitably qualified experienced scientists in appropriately equipped and authorized facilities. The burden of safe use of this material rests entirely with the user. MedChemExpress disclaims all liability for any damage resulting from handling or from contact with this product.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。
黄芩素对人乳腺癌细胞系MDA-MB-231_侵袭、迁移、上皮间充质转化的调控作用及其机制
黄芩素对人乳腺癌细胞系MDA -MB -231侵袭、迁移、上皮间充质转化的调控作用及其机制陈林1，2，梁秋果1，2，吉杨丹1，2，王恒1，21 黔南民族医学高等专科学校基础医学部，贵州都匀558013；2 黔南州天然产物与组分功效重点实验室摘要：目的 观察黄岑素对人乳腺癌细胞系MDA -MB -231的侵袭、迁移及上皮间充质转化（EMT ）的调控作用，探讨其可能作用机制。
方法 取对数生长期MDA -MB -231细胞分为一组、二组、三组及对照组，一组、二组、三组分别加入2.5、5、10 μmol /L 的黄岑素，对照组不做任何处理。
培养48 h 时采用划痕修复实验观察四组细胞迁移能力、采用Transwell 侵袭实验观察四组细胞侵袭能力，采用Western Blotting 法检测细胞EMT 标志物波形蛋白（vimentin ）及E -钙黏蛋白（E -cadherin ）、整合素αv 、β3、磷酸化黏着斑激酶（p -FAK ）、磷酸化磷脂酰肌醇3激酶（整合素p -PI3K ）。
结果 与对照组相比，黄岑素组细胞迁移率降低、侵袭细胞数少，细胞E -cadherin 相对表达量高，vimentin 、整合素αv 、整合素β3、p -FAK 、p -PI3K 蛋白相对表达量低，且呈剂量依赖性（P 均<0.05）。
结论 黄芩素抑制MDA -MB -231细胞的侵袭、迁移及EMT 。
黄岑素可能通过抑制整合素αv 、整合素β3表达，进一步抑制p -FAK 、p -PI3K 蛋白表达，抑制MDA -MB -231的侵袭、迁移及EMT 。
关键词：黄芩素；乳腺癌；细胞侵袭；细胞迁移；上皮间质转化；波形蛋白；E -钙黏蛋白；整合素αv 、整合素β3；黏着斑激酶；磷脂酰肌醇3激酶doi ：10.3969/j.issn.1002-266X.2024.06.003中图分类号：R965.1 文献标志码：A 文章编号：1002-266X （2024）06-0010-04Regulatory effects of baicalein on invasion ， migration ， and EMT in human breast cancer cell line MDA -MB -231CHEN Lin 1， LIANG Qiuguo ， JI Yangdan ， WANG Heng1 Department of Basic Medicine ， Qiannan Medical College for Nationalities ， Duyun 558013， ChinaAbstract ： Objective To investigate the regulatory effects of baicalein on the invasion ， migration ， and epithelial -mesenchymal transition （EMT ） of human breast cancer cell line MDA -MB -231 and to explore its potential mechanism of action. Methods MDA -MB -231 cells in the logarithmic growth phase were divided into the Group 1， Group 2， Group 3， and Control group. Baicalein was added to cells in the Group 1， Group 2， and Group 3 at concentrations of 2.5， 5， and 10 μmol /L ， respectively ， while cells in the Control group were not treated. After 48 h of incubation ， Scratch repair experi‐ment was used to observe cell migration capacity ， Transwell invasion experiment was performed to assess cell invasion ca‐pacity ， and Western blotting was utilized to detect the expression levels of EMT markers including vimentin and E -cad‐herin ， as well as integrin αv ， integrin β3， phosphorylated focal adhesion kinase （p -FAK ）， and phosphorylated phosphati‐dylinositol -3 kinase （p -PI3K ） proteins. Results Compared with the control group ， the cell migration rate decreased ， the number of invading cells decreased ， the relative expression level of E -cadherin was higher ， and the relative expression levels of vimentin ， integrin αv ， integrin β3， p -FAK ， and p -PI3K protein were lower in the baicalein group ， with a dose -de‐pendant manner （all P <0.05）. Conclusions Baicalein inhibits the invasion ， migration ， and EMT of MDA -MB -231cells. Baicalein may inhibit the expression of integrin αv ， integrin β3， and further inhibit the expression of p -FAK and p -PI3K proteins ， thereby inhibiting the invasion ， migration ， and EMT of MDA -MB -231 cells.Key words ： baicalein; breast carcinoma; cell invasion; cell migration; epithelial -mesenchymal transition; vimentin;基金项目：黔南民族医学高等专科学校校基金（qnyz202013，qnyz202206）；黔南民族医学高等专科学教育教学科研基金项目（qnyzjx202205）；黔南民族医学高等专科学校大学生科技创新项目（qnyz202201）。
胃癌脂代谢通路基因表达的转录组学高通量分析
胃癌脂代谢通路基因表达的转录组学高通量分析向丽娟;汪圣毅;包楚阳;张焱;韩坤;刘虎【摘要】目的探讨胃癌(GC)脂代谢(LM)通路的基因表达情况.方法转录组测序筛选8例GC及4例癌旁组织之间的差异表达基因,京都基因与基因组百科全书(KEGG)富集分析GC脂代谢相关通路中的关键基因(KGS).结果高通量测序获得3 198个长度大于200 bp的差异表达基因.KEGG富集分析发现6个显著富集代谢通路,其中脂肪消化与吸收代谢通路有9个基因(MOGAT3、FABP2、FABP1、■显著上调,2个基因(LIPF、PLA2G1B)显著下调.结论GC脂代谢关键基因表达的异常状态为寻求胃癌诊断标志物提供了线索.%Objective To investigate the gene expression of gastric cancer (GC) lipid metabolism (LM) pathways. Methods Transcriptome sequencing was used to screen the differentially expressed genes in 8 cases of gastric cancer and 4 cases of adjacent tissues, and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis was performed to explore the key genes in lipid metabolism related pathways in gastric cancer.ResultsHigh-throughput sequencing obtained 3198 differentially expressed genes with a length greater than 200 bp.KEGG enrichment analysis found six significantly enriched metabolic pathways, of which nine genes (MOGAT3, FABP2, FABP1, APOA4, NPC1L1, PLA2G2A, ABCG5, PLA2G4A, PLA2G12B) were significantly up-regulated in fat digestion and absorption metabolic pathway, and 2 genes (LIPF, PLA2G1B) was significantly downregulated. Conclusion Abnormal expression of key genes in GC lipid metabolism provides clues to the diagnosis markers of gastric cancer.【期刊名称】《安徽医科大学学报》【年(卷),期】2019(054)001【总页数】5页(P5-9)【关键词】胃肿瘤;转录组测序;脂代谢;关键基因【作者】向丽娟;汪圣毅;包楚阳;张焱;韩坤;刘虎【作者单位】安徽医科大学第一附属医院肿瘤内科, 合肥 230022;安徽医科大学第一附属医院普外科, 合肥 230022;安徽医科大学第一附属医院肿瘤内科, 合肥230022;北京诺禾致源科技股份有限公司, 北京 100080;北京诺禾致源科技股份有限公司, 北京 100080;安徽医科大学第一附属医院肿瘤内科, 合肥 230022;中国科学技术大学附属第一医院西区(安徽省肿瘤医院), 合肥 230031【正文语种】中文【中图分类】R735.2胃癌(gastric cancer,GC)是世界第五大恶性肿瘤和第三大常见癌症死亡原因[1]。
26291346_基于UPLC-MS
Abstract: A UPLC-MS/MS method was established to quantitatively determine the content of alliin in animal plasma to study whether alliin and alliin in garlic enteric preparations can react to produce the active ingredient allicin in the in vivo environment. Methods Reversed-phase C18 column (Waters ICQUITY UPLC BEH, 100 × 2.1 mm, 1.7μm), column temperature: 40 ℃, flow rate: 0.15 mL/min, injection volume: 2μl, Mobile phase: 0.1% formic acid (A)-acetonitrile (B), gradient elution; mass spectrometry ionization: ESI+, determination of allicin in rat plasma . Results The results of two parallel experiments of garlic enteric preparation and enzymatic garlic powder showed that in the garlic enteric preparation with allinase, the plasma concentration of alliin in the blood of rats was significantly lower. Conclusion A UPLC-MS/MS method for the quantitative determination of alliin in animal plasma has been established. Alliin and alliin in garlic enteric-coated preparations can react in vivo.Key words: Garlic enteric preparation; garbonine; UPLC-MS-MS基于UPLC-MS/MS大蒜肠溶制剂中蒜氨酸、蒜酶体内反应情况研究杨亮1，胡小霞4 ，宋百灵4，关明3，李新霞2*（1.新疆警察学院 新疆 乌鲁木齐 8300112.新疆医科大学药学院 新疆 乌鲁木齐 8300113.新疆师范大学化学化工学院 新疆 乌鲁木齐 8300544.新疆医科大学中心实验室 新疆 乌鲁木齐 830011）Study on the Reaction of Garlic and Uterine in the UPLC-MS / MS of Garlic SausolYANG Liang 1，HU Xiaoxia 4 ，SONG Bailing 4，GUAN Ming 3，LI Xinxia 2*(1. Xinjiang Police College, Urumqi 830054, Xinjiang China2.Chemistry and Chemical Engineering of Xinjiang Normal University College, Urumqi 830054, Xinjiang China3.School of Pharmacy, Xinjiang Medical University, Urumqi 830011, Xinjiang China4.Central Laboratory of Xinjiang Medical University, Urumqi 830011, Xinjiang China ）摘要：目的 建立定量测定动物血浆中蒜氨酸含量的UPLC-MS/MS 方法，研究大蒜肠溶制剂中蒜氨酸、蒜酶能否在体内环境下反应生成活性成分大蒜辣素。
蔓马缨丹挥发油GC-MS分析及其生物活性
蔓马缨丹挥发油GC-MS 分析及其生物活性艾彩霞1谭聪丽2邹坤林1吴奉奇1*（1华南农业大学林学与风景园林学院，广东广州510642；2东莞职业技术学院，广东东莞523808）摘要蔓马缨丹是我国华南地区常见的园林绿化灌木。
本文采用水蒸气蒸馏法从蔓马缨丹枝叶中提取挥发油，通过GC-MS 分析其化学组成，并分别测定其抗细菌和抗线虫活性。
结果表明：蔓马缨丹枝叶挥发油的得率为0.075%（以鲜重为基础），通过气相色谱与质谱联用技术共分析并鉴定出39种化学成分。
其中，含量较高的成分为β-cubebene 和β-elemene ，相对含量分别达到19.94%、19.61%。
抗细菌活性结果表明，蔓马缨丹挥发油对青枯病菌、番茄疮痂病菌以及黄瓜细菌性角斑病菌均表现出一定程度的抑制活性，其中对番茄疮痂病菌的生长抑制效果相对最好，抑菌圈直径达到（30.40±2.78）mm 。
另外，蔓马缨丹挥发油对南方根结线虫表现出了一定的致死活性，在24h 内致死中浓度为（33.07±2.12）mg/mL 。
本研究结果可为蔓马缨丹资源的综合开发与利用提供思路，为植物源农药的开发奠定理论基础。
关键词蔓马缨丹；挥发油；GC-MS ；抗细菌活性；杀线虫活性中图分类号S435.132文献标识码A文章编号1007-5739（2024）02-0051-05DOI ：10.3969/j.issn.1007-5739.2024.02.014开放科学（资源服务）标识码（OSID ）：GC-MS Analysis of Volatile Oil from Lantana montevidensis and Its Antibacterialand Nematicidal ActivitiesAI Caixia 1TAN Congli 2ZOU Kunlin 1WU Fengqi 1*(1College of Forestry and Landscape Architecture,South China Agricultural University,Guangzhou Guangdong 510642;2Dongguan Polytechnic,Dongguan Guangdong 523808）Abstract Lantana montevidensis is a common landscaping shrub in southern China.In this study,the volatile oilwas extracted from the branches and leaves of L.montevidensis by hydro-distillation.Its chemical composition wasanalyzed by GC-MS,and its antibacterial and nematicidal activities were determined respectively.The results showed that the yield of volatile oil from the branches and leaves of L.montevidensis was 0.075%(based on fresh weight),and 39chemical components were identified from the volatile oil through GC-MS analysis.Among them,the relative content of β-cubebene was the highest,followed by β-elemene,which reached 19.94%and 19.61%,respectively.The results ofantibacterial activity showed that the volatile oil of L.montevidensis exhibited a certain inhibitory activity against Ralstonia solanacearum ,Xanthomonas vesicatoria and Pseudomonas lachrymans .Among them,the growth inhibition effect on X.vesicatoria was relatively best,and the diameter of inhibitory zone reached (30.40±2.78)mm.In addition,the volatile oil showed a certain nematicidal activity against Meloidogyne incognita ,with the LC 50of (33.07±2.12)mg/mL within 24hours.These results of this study could provide ideas for the comprehensive development and utilization of L.montevidensis resources,and lay a theoretical basis for the development of plant-derived pesticides.KeywordsLantana montevidensis ;volatile oil;GC-MS;antibacterial activity;nematicidal activity蔓马缨丹（Lantana montevidensis ）为马鞭草科马缨丹属常绿灌木，别名紫花马缨丹、小叶马缨丹、铺地臭金凤等，原产地位于美洲的热带和亚热带[1]。
SCI_Chem 影响因子
Abbreviated JournalTitle(linked to journal information)Total CitesImpact Factor5-YearImpactFactor Immediacy Index综合1Nature 0028-0836********.59738.1599.2432Science0036-807550848931.02733.587 6.6913P Natl Acad Sci Usa 0027-84245349519.73710.583 1.893化学综合1Chem Rev 0009-266511259641.29845.79514.3352Nat Mater 1476-11224634835.74942.3768.4113Nat Nanotechnol 1748-33872192031.1736.011 5.8764Chem Soc Rev 0306-00124764624.89230.1817.9975Prog Mater Sci 0079-6425592123.19422.3337.2176Nat Chem 1755-4330865221.75723.02 5.5327Accounts Chem Res 0001-48424211220.83324.633 5.2958Nano Today 1748-0132294417.68918.1920.7849Annu Rev Mater Res 1531-7331525916.17914.4950.66710Surf Sci Rep 0167-5729411515.33322.2817.7511Adv Mater 0935-96489195214.82913.86 2.55712Mat Sci Eng R 0927-796X 485013.90218.9740.66713Angew Chem Int Edit 1433-785122989413.73413.56 2.95914Annu Rev Phys Chem 0066-426X 700213.36518.121 4.13815Nano Lett 1530-69848843113.02514.132 2.47116Acs Nano 1936-0851*******.06212.524 1.9417Energ Environ Sci 1754-56921284911.65312.462 3.08718Coordin Chem Rev 0010-85452560111.01612.257 2.29419J Am Chem Soc 0002-786343128610.67710.237 2.16420Nat Prod Rep 0265-0568660910.17810.072 2.38521Adv Energy Mater 1614-6832199510.04310.05 2.11822Adv Funct Mater 1616-301X 347589.76510.342 1.81523Med Res Rev 0198-632532979.5839.978 1.81124Npg Asia Mater 1884-40493019.0428.556 2.41425Annu Rev Anal Chem 1936-132711498.612.2830.69626Top Curr Chem 0340-102255078.456 6.205 4.27327Chem Sci 2041-652048458.3148.33 2.77128Chem Mater 0897-4756746518.2387.627 1.12329J Photoch Photobio C 1389-556720268.06911.9520.7530Small 1613-6810181377.8238.084 1.42931Prog Photovoltaics 1062-799545357.7127.023 3.22332J Control Release 0168-3659297557.6338.078 1.13633Annu Rev Chem Biomol 1947-54383317.5127.512 1.04534Int Mater Rev 0950-660822557.487.1491.188RankISSNJCR Data35Chemsuschem1864-563150567.4757.951 1.189 36Prog Solid State Ch0079-678614747.429 3.3380 37Nano Res1998-012430317.3927.8010.979 38Prog Surf Sci0079-681619047.1369.140.273 39Adv Carbohyd Chem Bi0065-23188337.133 5.8460.75 40Green Chem1463-926215554 6.828 6.992 1.269 41Adv Organomet Chem0065-3055841 6.758.9410 42Curr Opin Colloid In1359-02944670 6.6297.0360.884 43J Phys Chem Lett1948-71858575 6.585 6.651 1.301 44Top Organometal Chem1436-60021152 6.384 1.762 45Chem Commun1359-7345122728 6.378 6.226 1.53 46Catal Rev0161-49402529 6.37510.1750.889 47Trac-Trend Anal Chem0165-99367327 6.351 6.7610.92 48Nanoscale2040-33647835 6.233 6.262 1.167 49Adv Colloid Interfac0001-86867115 6.1698.01 1.32 50Org Lett1523-706073440 6.142 5.563 1.572 51Mater Today1369-70213769 6.0718.677 1.977 52Prog Nucl Mag Res Sp0079-65651993 6.022 6.065 1.389 53Crit Rev Solid State1040-8436744 5.9477.3681 54Carbon0008-622332742 5.868 6.35 1.197 55Chem-Eur J0947-653960788 5.831 5.623 1.241 56Appl Catal B-Environ0926-337323011 5.825 6.0310.965 57J Catal0021-951734516 5.787 6.249 1.025 58Wires Comput Mol Sci1759-0876570 5.738 5.738 3.518 59Lab Chip1473-019716485 5.697 6.136 1.256 60Anal Chem0003-270096794 5.695 5.7690.948 61J Med Chem0022-262359227 5.614 5.383 1.225 62Adv Synth Catal1615-415015502 5.535 5.323 1.109 63Curr Opin Solid St M1359-02862508 5.4387.3290.913 64Biosens Bioelectron0956-566322068 5.437 5.389 1.105 65J Chem Theory Comput1549-961811067 5.389 5.936 1.067 66Biomacromolecules1525-779724209 5.371 5.750.721 67Acs Catal2155-54351461 5.265 5.265 1.222 68Adv Catal0360-05641399 5.25 5.2860 69Chemcatchem1867-38802718 5.181 5.3070.941 70Mrs Bull0883-******** 5.024 5.590.569 71Acs Appl Mater Inter1944-82448635 5.008 5.040.683 72Electroanal Chem0070-977837757.50.25 73J Comb Chem1520-47662925 4.933 3.10274Int Rev Phys Chem0144-235X1524 4.92 5.595 2.231 75J Phys Chem C1932-744778595 4.814 5.1520.738 76Pharm Res-Dordr0724-874119035 4.742 5.0460.735 77Cryst Growth Des1528-748322310 4.689 4.8730.869 78Sol Energ Mat Sol C0927-024818447 4.63 5.205 1.215 79J Chromatogr A0021-967363419 4.612 4.5820.71480Inorg Chem0020-166985446 4.593 4.5510.956 81Bioconjugate Chem1043-180213900 4.58 4.7960.768 82Chem-Asian J1861-47286084 4.572 4.488 1.04683J Org Chem0022-326396723 4.564 4.135 1.101 84Anal Chim Acta0003-267039448 4.387 4.3440.684 85Chem Rec1527-89991375 4.377 4.814 1.533 86Int J Plasticity0749-64195276 4.356 4.70.862 87J Chem Inf Model1549-959611250 4.304 4.0670.795 88Langmuir0743-7463106920 4.187 4.4160.793 89Organometallics0276-733339735 4.145 3.653 1.004 90Ultraschall Med0172-46141247 4.116 2.723 1.286 91J Flow Chem2062-249X61 4.091 4.091 1.143 92Curr Med Chem0929-867312773 4.07 4.4710.627 93Struct Bond0081-59931899 4.068 4.24894Mar Drugs1660-33971871 3.978 3.9110.428 95Analyst0003-265416152 3.969 3.9040.785 96Acta Mater1359-645434860 3.941 4.3950.781 97Soft Matter1744-683X15943 3.909 4.35 1.013 98Crystengcomm1466-803312988 3.879 4.0690.863 99Acs Chem Neurosci1948-7193634 3.871 3.9570.729 100Nanotechnology0957-448434133 3.842 3.8380.697 101Org Electron1566-11995856 3.836 4.0210.63 102J Comput Chem0192-865124682 3.835 4.4010.847 103Phys Chem Chem Phys1463-907640969 3.829 3.976 1.052 104Faraday Discuss1359-66405758 3.821 4.148 2.369 105Dalton T1477-922638660 3.806 3.8890.947 106Catal Sci Technol2044-47531079 3.753 3.753 1.024 107Sci Technol Adv Mat1468-69962352 3.752 3.6440.235 108Chembiochem1439-42279616 3.74 3.670.78 109Curr Top Med Chem1568-02664850 3.702 3.8850.655 110Chem Res Toxicol0893-228X10785 3.667 4.0130.807 111Anal Bioanal Chem1618-264221971 3.659 3.7560.727 112Acs Comb Sci2156-8952379 3.636 3.6360.596 113Corros Sci0010-938X18210 3.615 4.0160.757 114J Phys Chem B1520-6106119722 3.607 3.7020.66 115J Am Soc Mass Spectr1044-03058760 3.592 3.5030.925 116J Cheminformatics1758-2946315 3.59 3.6710.314 117Org Biomol Chem1477-052018355 3.568 3.490.952 118Ultrasound Obst Gyn0960-76928490 3.557 3.7080.756 119Colloid Surface B0927-776510312 3.554 3.4170.707 120Int J Hydrogen Energ0360-319933119 3.548 4.0860.584 121Sensor Actuat B-Chem0925-400529909 3.535 3.6680.527 122Dyes Pigments0143-72087664 3.532 3.4330.897 123Expert Opin Ther Pat1354-37761742 3.525 2.5230.6 124Ultrason Sonochem1350-41775008 3.516 3.708 1.234125J Phys Chem Ref Data0047-26894996 3.5 3.7790.391 126Eur J Med Chem0223-523414818 3.499 3.8490.541 127Talanta0039-914026966 3.498 3.7330.531 128Food Hydrocolloid0268-005X6307 3.494 3.5250.953 129Drug Des Dev Ther1177-8881377 3.4860.256 130Carbohyd Polym0144-861718471 3.479 3.9420.665 131Microchim Acta0026-36724743 3.434 2.8830.5 132Appl Catal A-Gen0926-860X27726 3.41 3.910.506 133J Mech Phys Solids0022-509610460 3.406 3.7460.784 134Pure Appl Chem0033-454513333 3.386 3.1150.382 135Micropor Mesopor Mat1387-181115134 3.365 3.4140.869 136J Biol Inorg Chem0949-82574011 3.353 3.3550.713 137Chemphyschem1439-423511279 3.349 3.3880.768 138Eur J Org Chem1434-193X19346 3.344 3.1370.746 139Food Chem0308-814641375 3.334 4.0720.589 140Acs Med Chem Lett1948-58751087 3.311 3.3180.699 141Future Med Chem1756-89191081 3.31 3.2450.933 142J Nat Prod0163-386419898 3.285 3.2670.787 143Electrophoresis0173-083516985 3.261 2.8690.479 144Bioanalysis1757-61801318 3.253 3.0440.723 145J Mass Spectrom1076-51745573 3.214 3.2270.495 146J Inorg Biochem0162-013410014 3.197 3.430.672 147J Mol Catal A-Chem1381-116917999 3.187 3.3190.496 148J Colloid Interf Sci0021-979744929 3.172 3.390.747 149J Anal Atom Spectrom0267-94777362 3.155 2.9530.725 150Sep Purif Rev1542-2119222 3.154 3.5430.3 151J Pharm Sci-Us0022-354917986 3.13 3.3850.6 152Eur J Inorg Chem1434-194816310 3.12 2.9510.728 153Cement Concrete Res0008-884613854 3.112 3.7460.441 154Curr Org Chem1385-27283953 3.039 3.2220.253 155Isr J Chem0021-21481263 3.025 1.9460.478 156Mar Chem0304-420368723 3.3150.466 157Catal Today0920-586123325 2.98 3.4640.515 158Phytomedicine0944-71135244 2.972 3.2580.401 159New J Chem1144-054610014 2.966 2.920.698 160J Pharmaceut Biomed0731-708514648 2.947 2.8530.562 161Photoch Photobio Sci1474-905X4541 2.923 2.810.538 162Catal Commun1566-73679190 2.915 3.3280.535 163Mater Design0261-30699587 2.913 2.8050.703 164J Agr Food Chem0021-856176046 2.906 3.2880.417 165Bioorgan Med Chem0968-089624911 2.903 3.1510.617 166Crit Rev Anal Chem1040-8347979 2.892 3.690.591 167Microchem J0026-265X3428 2.879 2.85 1.048 168Mini-Rev Med Chem1389-55752893 2.865 2.9210.496 169Mol Divers1381-19911289 2.861 3.090.44170Chemmedchem1860-71793723 2.835 3.0750.788 171J Mol Catal B-Enzym1381-11774943 2.823 2.8050.542 172Scripta Mater1359-646219677 2.821 3.1450.534 173Adv Phys Org Chem0065-3160391 2.818 2.609174Electroanal1040-039710646 2.817 2.8620.462 175Fuel Process Technol0378-******** 2.816 3.4930.49 176Tetrahedron0040-402052981 2.803 2.8990.636 177Beilstein J Org Chem1860-53971405 2.801 2.4750.386 178J Phys Chem A1089-563955641 2.771 2.8560.658 179J Ethnopharmacol0378-874121278 2.755 3.3220.519 180Org Process Res Dev1083-61604311 2.739 2.6670.808 181J Supercrit Fluid0896-84466044 2.732 3.1380.472 182Medchemcomm2040-2503690 2.722 2.7220.603 183Adv Inorg Chem0898-******** 2.714 3.3780.25 184J Electroanal Chem1572-665721687 2.672 2.6760.545 185Int J Photoenergy1110-662X945 2.663 2.240.671 186Synlett0936-521417034 2.655 2.4520.604 187Environ Chem1448-25171390 2.652 2.701 1.075 188Opt Mater Express2159-3930593 2.616 2.6220.815 189Anti-Cancer Agent Me1871-52061386 2.610.239 190Top Catal1022-55284896 2.608 2.7080.238 191J Sep Sci1615-93068094 2.591 2.6380.296 192Anal Biochem0003-269739746 2.582 2.9690.558 193Rsc Adv2046-20691816 2.562 2.5670.695 194J Anal Appl Pyrol0165-23705102 2.56 3.0740.447 195Nanoscale Res Lett1931-75733998 2.524 2.7830.2980951-419813285 2.509 2.6110.49 196Rapid Commun Mass Sp196Sci Adv Mater1947-2935553 2.509 2.5610.301 198React Funct Polym1381-51484515 2.505 2.6530.282 199J Chem Technol Biot0268-25756796 2.504 2.4790.573 200Synthesis-Stuttgart0039-788117999 2.5 2.3840.615 201Microsc Microanal1431-92762043 2.495 3.0770.276 202J Chromatogr B1570-023220776 2.487 2.90.319 203Phytochem Analysis0958-03441895 2.48 2.280.292 204Adv Heterocycl Chem0065-2725888 2.478 2.6170.455 205Chem Biol Drug Des1747-02771940 2.469 2.4090.511 206Int J Mol Sci1422-00674706 2.464 2.7320.313 207Ultrasound Med Biol0301-56297839 2.455 2.8440.251 208Gold Bull0017-15571073 2.434 3.1220.04 209Molecules1420-30497552 2.428 2.6790.329 210Plasmonics1557-1955877 2.425 2.9880.525 211J Photoch Photobio A1010-603013061 2.416 2.6910.299 212Tetrahedron Lett0040-403973763 2.397 2.3760.561 213J Alloy Compd0925-838839264 2.39 2.1610.629 214Phys Status Solidi-R1862-62541437 2.388 2.4320.527215Fluid Phase Equilibr0378-******** 2.379 2.3380.544 216Solvent Extr Ion Exc0736-******** 2.375 2.6090.345 217Beilstein J Nanotech2190-4286309 2.374 2.3740.573 218Plant Food Hum Nutr0921-96681569 2.358 2.7620.25 219Acta Pharmacol Sin1671-40835577 2.354 2.5210.596 220Planta Med0032-094311009 2.348 2.4620.304 221Appl Clay Sci0169-13175590 2.342 2.7980.337 222Bioorg Med Chem Lett0960-894X33460 2.338 2.4270.584 222Macromol Mater Eng1438-74922983 2.338 2.3920.509 222Mol Inform1868-1743344 2.338 2.3460.347 225Russ Chem Rev+0036-021X3092 2.299 2.8130.204 226J Chem Thermodyn0021-96145905 2.297 2.2560.735 227Constr Build Mater0950-06187337 2.293 2.8180.391 228Chemometr Intell Lab0169-74394880 2.291 2.4320.253 229Biophys Chem0301-46224822 2.283 2.0940.649 230Arab J Chem1878-5352299 2.2660.343 231J Ginseng Res1226-8453349 2.2590.34 232Materials1996-19441176 2.247 2.3380.222 233Catal Lett1011-372X9373 2.244 2.2610.351 234Theor Chem Acc1432-881X5484 2.233 3.1510.812 235Fitoterapia0367-326X4706 2.231 2.1390.349 236Mater Lett0167-577X23419 2.224 2.3220.489 237Food Addit Contam A1944-00495142 2.22 2.4420.508 238J Biomol Screen1087-05712357 2.207 2.0890.719 239Platin Met Rev0032-1400735 2.194 2.4760.579 240J Nanopart Res1388-07645724 2.175 2.7210.222 241J Mater Sci0022-246131538 2.163 2.10.543 242Adv Quantum Chem0065-3276869 2.161 1.6940.308 242Colloid Polym Sci0303-402X5657 2.161 2.1140.433 244Chem Phys Lett0009-261455163 2.145 2.150.485 244J Ind Eng Chem1226-086X2264 2.145 1.9550.329 246Tetrahedron-Asymmetr0957-416611707 2.115 2.1430.384 247Appl Surf Sci0169-433231193 2.112 2.0990.33 248Synthetic Met0379-677913916 2.109 2.1020.334 249Colloid Surface A0927-775718414 2.108 2.3330.333 249Mat Sci Eng A-Struct0921-509340513 2.108 2.3490.307 251J Anal Toxicol0146-47602660 2.107 1.7580.429 252Solid State Nucl Mag0926-20401202 2.1 2.0570.711 253J Food Compos Anal0889-15753737 2.088 2.7430.19 254J Environ Monitor1464-03254378 2.085 2.1370.322 255Mater Chem Phys0254-058417174 2.072 2.3950.286 256J Pept Sci1075-26171942 2.071 1.8280.434 257Phytother Res0951-418X8059 2.068 2.4380.444 258Nano-Micro Lett2150-5551205 2.057 1.910.35 259Solid State Ionics0167-273820728 2.046 2.5640.26260Carbohyd Res0008-621514176 2.044 2.1780.357 261J Solid State Chem0022-459618166 2.04 2.2950.392 262Curr Org Synth1570-1794673 2.038 2.9140.76 263Ultrasonics0041-624X3651 2.028 2.0540.456 264Smart Mater Struct0964-17267120 2.024 2.3770.289 265Inorg Chem Commun1387-70036416 2.016 1.8810.434 266Appl Organomet Chem0268-26052866 2.011 1.9220.272 267Electrochem Solid St1099-00628883 2.01 2.0260.596 268J Chem Eng Data0021-956815169 2.004 2.1150.295 269Comb Chem High T Scr1386-207314532 1.9750.268 269J Organomet Chem0022-328X217932 1.9920.527 271Thermochim Acta0040-603111408 1.989 2.0460.327 272J Mol Model1610-29403157 1.984 2.3010.378 273J Therm Anal Calorim1388-61509934 1.982 1.7420.243 274Int J Fatigue0142-11235248 1.976 1.9740.352 275J Vib Control1077-54631649 1.966 1.7360.672 276Chem Phys0301-010412935 1.957 2.0590.592 277J Mater Process Tech0924-013618426 1.953 2.1760.332 277Sensors-Basel1424-82207082 1.953 2.3950.321 279Biomed Chromatogr0269-38792861 1.945 1.8150.385 280J Fluorine Chem0022-11394998 1.939 1.9490.465ArticlesCited Half-life Eigenfactor ®Metrics ScoreArticleInfluenc e® Score8699.6 1.5750820.8448329.7 1.3598717.71238018 1.55663 4.8921768.20.2266114.294141 5.20.2278819.481121 3.70.1543615.607390 3.50.178418.8542370.015018.643126 2.40.054018.927207 6.50.108177.90837 3.20.01489 5.62318>10.00.013647.55389.40.008828.821867 5.10.27819 4.24368.40.00872 6.542227 5.50.53637 3.497299.90.01888.1211078 4.40.37491 5.1891191 2.40.20333 4.012473 1.80.05534 3.461368.20.03818 3.07130997.70.83183 2.99465 5.90.01757 3.141169 1.40.00944 3.344569 4.20.12336 3.006377.20.00647 2.73229 1.90.00155 3.27323 3.90.00716 4.441557.70.01045 2.068458 1.40.02121 2.833576 6.70.15215 2.032167.90.00342 3.148457 3.60.07856 2.503112 4.60.01202 1.97501 6.90.05008 1.9062220.00197 2.73916>10.00.003282.792Eigenfactor®Metrics286 2.60.0208 2.0046>10.00.00142 1.13896 2.80.01517 2.301119.20.00397 3.974>10.00.00086 1.894 44940.03848 1.5233>10.00.00076 2.537437.60.01013 2.301 63220.04884 2.393 2150.003483173 4.80.28954 1.5629>10.00.00211 3.009 138 5.80.01695 1.794 1015 1.70.02966 1.597 508.20.01226 2.37 160850.18182 1.40244 5.40.01448 3.213188.30.00431 2.295 107.10.00156 2.34 674 6.40.06437 1.6 1916 4.10.1766 1.469 480 5.40.05059 1.419 284>10.00.04014 1.60356 1.20.00194 1.703 617 3.70.05475 1.603 14797.80.17236 1.533 8907.80.09182 1.35 404 4.40.04405 1.352 239.20.00403 2.705 448 4.10.05929 1.252 507 3.50.04948 1.865 480 5.30.05919 1.416 315 1.30.00585 1.6362>10.00.00057 1.543 255 2.10.01222 1.495 116 6.20.01779 2.376 953 2.30.03563 1.2844>10.00.00016 2.2160 5.10.006940.708137.90.00319 2.303 3283 3.40.34957 1.353 2798.70.02859 1.299 773 3.90.057280.943 493 5.30.04212 1.304 11447.10.090460.92115617.50.124780.98 259 5.70.03346 1.295 372 2.80.02555 1.219 1289>10.00.12482 1.03 7277.10.06585 1.03830 5.80.00343 1.39794 6.80.01439 1.685 303 6.60.019140.892 2119 6.70.21487 1.164 9987.10.059110.76263 3.40.002370.436140.000190.962 475 5.50.03101 1.1898.60.00225 1.225 194 2.50.00680.908 817 6.60.031350.985 68170.09849 1.714 1358 2.50.073 1.334 1194 2.60.032550.749 10720.00309 1.26 1021 4.40.12987 1.194 459 3.20.02416 1.192 2618.90.03446 1.396 1804 3.70.15067 1.296 1418.60.01298 1.609 1709 4.50.08330.842 327 1.30.00320.94181 4.90.00904 1.23 327 4.70.03579 1.258 17750.0131 1.044 2597.10.02119 1.078 877 4.30.068460.99799 1.40.001410.915 449 6.30.028910.786 16157.50.18356 1.081 22860.020170.96535 1.90.00176 1.224 1160 3.80.055440.914 201 6.30.017610.949 426 4.10.025740.772 2120 3.70.074070.708 1016 5.80.054290.757 321 5.50.013530.63690 3.30.006210.726 184 4.80.010070.73123>10.00.00228 1.513 610 3.80.032170.72 842 5.40.057730.829 213 5.40.01270.77439 2.40.001731002 4.80.033670.729 208 4.30.00930.537 5247.60.043570.93 116>10.00.02104 1.812 173>10.00.013330.936 589 5.30.032210.807 108 6.10.009190.931 487 4.70.03951 1.142 76450.047770.779 1666 5.20.091160.854 193 1.80.004620.921 120 2.20.004670.894 3338.70.027140.756 4327.10.027040.625 19520.003610.533 194 6.90.011710.909 2597.30.013360.716 266 6.80.026850.752 87080.070140.869 2187.70.01310.75610 5.60.00062 1.012 4189.20.026590.815 622 5.20.034970.666 1709.90.01712 1.222 178 5.80.009120.836 907.70.00320.65258>10.00.01221 1.371 4877.30.041850.896 187 5.60.009820.662 338 6.50.019280.711 443 6.30.026840.651 20850.01330.806 409 4.50.027060.735 774 3.20.034350.762 15287.90.107180.745 739 5.40.053960.715 227.60.001180.774 105 5.10.007480.647 129 4.90.00780.74475 3.50.002990.639212 3.70.013920.784 201 5.60.009290.599 500 6.30.06138 1.238 >10.00.00042 1.049 290 6.10.019640.625 251 5.60.017330.895 12498.40.075460.68 241 2.20.005560.628 1341 6.70.120620.829 651 6.90.026690.572 224 5.10.010210.672 290 5.30.013220.702 194 1.60.002660.7278>10.00.000620.792 314>10.00.019270.649 32830.001390.381 520 6.30.034550.62153 5.20.004350.904 200 1.30.002460.856 109 3.70.00563143 5.80.013670.825 439 4.20.025470.66 441>10.00.03210.853 17290.80.002020.494 1527.40.009010.741 624 2.40.016810.714 337 6.40.02850.71 173 1.90.002010.614 124 6.30.008010.593 2207.60.010810.602 4708.20.028730.596 221 5.20.00853 1.29 4957.50.036490.714 967.20.003150.52311>10.00.000450.543 184 3.50.006730.588 1064 2.80.017560.666 2437.60.014140.744 257.10.002380.868 105130.022770.574 10130.003550.834 2518.20.017620.63 16669.90.081330.508 1478 4.10.10840.548 14830.008560.8753427.80.015630.587 559.80.002470.6496 1.50.001250.668648.10.002270.561 178 6.20.010850.6 247>10.00.011750.526 202 5.20.013550.701 1484 5.40.069550.546 116 6.40.005740.60572 2.10.00140.58954>10.00.004010.856 351 6.60.011110.57 960 3.90.021660.681 1549.50.006150.597 5790.008180.646 6720.0008353 2.30.00061176 2.60.005320.633 1947.80.016490.569 223 5.60.014960.968 25280.006360.457 1626 5.50.049760.537 1977.10.008730.585 128 5.40.00580.57919>10.00.001080.734 650 3.70.017210.673 9419.10.050830.59113>10.00.00130.598 21090.007690.475 906>10.00.066080.687 350 3.90.005590.396 2247.80.01640.479 1789 5.50.074220.539 419>10.00.014550.491 579 6.80.034280.585 11717.30.084950.73 918.60.003920.471 458.60.00220.655 100 6.20.007370.666 335 5.10.012850.644 964 5.50.038290.59199 5.20.004810.478 302 6.60.012460.48640 2.10.000610.345 392>10.00.021350.719339>10.00.01560.489 5138.90.025150.615 50 4.50.001620.659 1368.50.005580.639 353 5.90.018730.713 495 4.80.011170.321 1147.60.003960.391 156 6.70.022520.706 508 6.50.027410.476 82 5.10.003380.472 410>10.00.020760.421 400>10.00.012770.531 463 4.70.008250.53 728 5.70.012880.253 2367.10.012090.669 180 3.80.004490.45 360>10.00.018270.679 2957.80.035210.653 950 3.40.026580.586 218 5.20.006840.446 2547.50.007820.487。
高效液相色谱-荧光分析法测定人体尿液中的墨蝶呤
高效液相色谱-荧光分析法测定人体尿液中的墨蝶呤崔盼盼;万益群【摘要】建立了人体尿液中墨蝶呤的高效液相色谱-荧光分析方法.尿液经乙腈处理,过0.45μm水相滤膜后定容,可进行液相色谱分析.色谱柱为Kiamonsil C18柱,以水-甲醇(80∶20,υ/υ)为流动相,流速为1.O mL/min,荧光检测波长为λex=425nm,λem=530nm.墨蝶呤含量在0.005-1.0μg/mL范围内与色谱峰面积呈良好的线性关系,线性回归方程为y=106x-328.02(r=0.9990),检测限是0.002μg/mL.其加标平均回收率在98.7%～106.8%之间,相对标准偏差小于7.34%.该方法简便,应用于胃癌病人和健康人尿样中墨蝶呤测定,结果较好.%The determination of sepiapterin in human urine by HPLC-FLD has been studied.The urine was filtered by 0.45 μm membrane after dealed withCH3CN, then the sample was analyzed by HPLC-FLD.The chromatographic column was Diamonsil C18, the moble phase was H2O-methanol( 80:20 ,v/v), the flow rate was 1.0 mL/min, the excitation and emission wavelengths were 425 nm and 530 nm, respectively.The linear range of sepiapterin was 0.005 - 1.0 μg/mL.The linear regression equation was y = 106x - 328.02 ( r = 0.999 0), and the limit of detection was 0.002 μg/mL.The average recoveries were in the range of 98.7％～ 106.8％ with the RSD below 7.34％.The proposed method was applied to the determination of sepiapterin in both the gastric cancer patients'urine samples and healthy human urine with satisfactory results.【期刊名称】《南昌大学学报（理科版）》【年(卷),期】2011(035)001【总页数】4页(P60-63)【关键词】墨蝶呤;人体尿液;高效液相色谱;荧光检测【作者】崔盼盼;万益群【作者单位】南昌大学,食品科学与技术国家重点实验室,江西,南昌,330047;南昌大学,食品科学与技术国家重点实验室,江西,南昌,330047;南昌大学,分析测试中心,江西,南昌,330047【正文语种】中文【中图分类】O657.7蝶呤类化合物(Pteridines)属于蝶啶的衍生物，分布于整个生物界，种类较多，但含量甚微，其中主要的几种蝶呤类化合物包括蝶呤(Pterin)、新蝶呤(Neopterin)、黄蝶呤(Xanthopterin)、异黄蝶呤(Isoxanthopterin)、蝶呤-6-羧酸(Pterin-6-carboxylic acid)、生物蝶呤(Biopterin)、墨蝶呤(Sepiapterin)和癌蝶呤(Oncopterin)等。
本刊参考文献著录格式
364中国艾滋病性病2021年4月第27卷第4期Chin J AIDS STD Vo丨.27 No.4 Apr 2021[5] ANGLIN MD, BURKE C, PERROCHET B, et al. History ofthe methamphetamine problem[j], J Psychoactive Drugs,2000,32(2)：137-141.[6] CHENG T, JOHNSTON C, KERR T, et al. Substance usepatterns and unprotected sex among street-involved youth in aCanadian setting：a prospective cohort study ^J. BMC PublicHealth,2016(16)：4.[7] BAILEY SL, GAO W, CLARK DB. Diary study of substanceuse and unsafe sex among adolescents with substance usedisorders[ J]. J Adolesc Health,2006,38( 3) ：213-297.[8] DUNN M, DAY C, BRUNO R, et al. Sexual and injecting riskbehaviours among regular ecstasy users [J]. Addict Behav, 2010,35(2)：157-160.[9] ZUCKERMAN MD, BOYER EW. HIV and club drugs inemerging adulthood [J]. Curr Opin Pediatr, 2012, 24 (2)：219-224.[10]郭巍，曲书泉，丁正伟，等.中国1995 — 2009年吸毒者艾滋病毒感染和梅毒流行趋势分析[J].中华流行病学杂志，2010,31(6)：666-669.[11] BAO YP, LIU ZM. Systematic review of HIV and HCVinfection among drug users in China[j]. Int J STD AIDS,2009,20(6)： 399-405.[12]葛琳，李东民，李培龙，等.2010-2015年中国艾滋病哨点监测人群HIV、梅毒和HCV感染状况分析[J].疾病监测，2017,32(2)：111-117.[13]许艳，王璐.国内外M0岁年龄组人群艾滋病流行特征及危险因素[J].中华流行病学杂志，2011,32(11): 1166-1169.[14] ZHUANG X, LIANG Y, CHOW EP, et al. HIV and HCVprevalence among entrants to methadone maintenance treatmentclinics in China：a systematic review and meta-analysis LJ]-BMC Infect Dis,2012( 12) ： 130.[15] BAO Y, LARNEY S, PEACOCK A, et al. Prevalence of HIV,HCV and HBV infection and sociodemographic characteristicsof people who inject drugs in China：A systematic review andmeta-analysis[j]. Int J Drug Policy,2019( 70)：87-93.L16] WANG BX, ZHANG L, WANG YJ, et al. Epidemiology of syphilis infection among drug users at methadone maintenancetreatment clinics in China：systematic review and meta-analysis[J]. Int J STD AIDS,2014,25(8) ：550-558.[17] ZHANG L, CHOW EP, JING J, et al. HIV prevalence inChina：integration of surveillance data and a systematic review[J ]. Lancet Infect Dis, 2013,13 (11) ： 955-963.[18] BAO YP, LIU ZM, LU L. Review of HIV and HCV infectionamong drug users in China [j]. Current opinion in psychiatry2010,23(3)：187-194.[19] ZHANG L, ZHANG D, CHEN W, et al. High prevalence ofHIV, HCV and tuberculosis and associated risk behavioursamong new entrants of methadone maintenance treatment clinicsin Guangdong Province, China[j]. PLoS One, 2013,8( 10) ：e76931. [20] LUO W, WU Z, POUNDSTONE K, et al. Needle and syringeexchange programmes and prevalence of HIV infection amongintravenous drug users in China [ J ]. Addiction ,2015,110 (Suppll)：61-67.[21 ]陈雯，凌莉，何群，等.广东省社区美沙酮维持治疗项目绩效评价与政策建议[J].中国卫生政策研究，2010,3(3) :39-44.[22] WANG L, GUO W, LI D, et al. HIV epidemic among drugusers in China：1995-2011 [J]. Addiction (Abingdon,England), 2015,110 Suppl l(l)：20-28.[23]樊盼英，汪宁.新型毒品滥用对艾滋病流行的影响[J].中华流行病学杂志，2010，31 (3): 340-343.[24]葛琳，崔岩，王璐，等.2012年全国艾滋病哨点吸毒人群血清学和性行为特征分析[J].中华流行病学杂志，2014, 35 (2):121-123.[25] KOESTERS SC, ROGERS PD, RAJASINGHAM CR. MDMA('ecstasy') and other 'club drugs'. The new epidemic [J]. PediatrClin North Am, 2002,49( 2) ： 415-433.1言息本刊参考文献著录格式凡文内引用他人的结果或结论，均应标注并在文末列出参考文献，只限亲自阅读的近期公开发表过的，未公开发表的文献不列入。
血清生物标志物在缺血缺氧性脑病新生儿中的研究进展
血清生物标志物在缺血缺氧性脑病新生儿中的研究进展兰雪，崔艳芳，陈国萍，于嘉，肇颖新(哈尔滨医科大学附属第一医院新生儿科，黑龙江哈尔滨150001)摘要：治疗性低温疗法作为低氧缺血性脑病(hypoxic ischemic encephalopathy,HIE)治疗标准的广泛引入，给临床医生带来了越来越大的压力，要求他们对发生的低氧损伤(hypoxic injury,H I)的程度和随之而来的脑病的严重程度做出早期和准确的评估。
然而，目前还没有任何一种基于血液的标志物足以检测HI或预测预后。
许多炎症蛋白、神经元特异性蛋白和MicroRNA表达可预测HIE病情变化，这些变化在出生的几小时至几天内迅速演变。
将临床数据与生化检测结果相结合是目前改善新生儿HIE的检测和预测结局的最可能途径。
本文总结了目前对HIE血清生物标志物的研究，显示了其预测HIE预后的潜力。
关键词：血清生物标记物；新生儿；缺血缺氧性脑病；研究进展中图分类号：R7222文献标识码：AResearch Progresses of Serum Biomarkers in Neonateswith Hypoxic Ischemic EncephalopathyLAN Xue,CUI Yanfang,CHEN Guoping,YU Jia,ZHAO Yingxin (Department of Neonatology,The First Affiliated Hospital of Harbin Medical University,Harbin150001,China) Abstract：The widespread introduction of therapeutic hypothermia as a standard of care for hypoxic ischemic encephalopathy(HIE)has created an increasing pressure on clinicians to make an early and accurate asse s ment ofthe degree of hypoxicinjury(HI)that occurs and the severity ofthe accompanyingencephalopathy.However,none of the blood-based markersisyetgoodenoughto accuratelydetectsignificantHIorpredictoutcomes.HIEisa s ociatedwith manypredictablechanges in inflammatory proteins,neuron-specific proteins,and MicroRNA expressions that evolve rapidly withinhoursto daysafterbirth.Thecombination of clinical data and biochemicaltestresultsis currentlythe mostpromising approachtoimprovethe detection and prediction of neonatal HIE outcomes.This paper summarizes the current research on SERUM biomarkers of HIE and shows its potentialtopredictHIEresults.Key words:；Serum biomarkers；Newborn；Hypoxic ischemic encephalopathy；Progress在新生儿低氧缺血性脑病(hypoxic ischemic encephalopathy,HIE)的管理中，最大的难点是对于HIE的预测、检测和分级，分级的结果会影响治疗干预的方式。
儿童急性髓系白血病的遗传基因异常及其意义
中国小儿血液与肿瘤杂志 ２０２１年 ６月第 ２６卷第 ３期 ＪＣｈｉｎａＰｅｄｉａｔｒＢｌｏｏｄＣａｎｃｅｒ，Ｊｕｎｅ２０２１，Ｖｏｌ２６，Ｎｏ．３
·１３１·
２ 异常基因在 ＭＲＤ监测中的作用 ２１ 融 合 基 因 ＲＵＮＸ１ＲＵＮＸ１Ｔ１／ｔ（８；２１）和 ＣＢＦＢＭＹＨ１１／ｉｎｖ（１６）／ｔ（１６；１６）均可用 于 治 疗 后 的 ＭＲＤ监测 。 ［１，８１１］ 诱导或巩固结束后，ＲＴｑＰＣＲ 检测其转录产物 ｍＲＮＡ拷贝数（ＡＢＬ做内参），较初 诊时降低 ＞３个 ｌｏｇ者预后良好。究竟在诱导后还 是巩固后降低 ＞３个 ｌｏｇ较有预后意义，视不同方案 而定。如果诱导结束后降低不足 ３个 ｌｏｇ，在巩固期 间继续降低，直到治疗完全结束后 ＜初诊时的 ４个 ｌｏｇ者预后仍好，提示连续监测的重要性。但如果将 ＲＵＮＸ１ＲＵＮＸ１Ｔ１和 ＣＢＦＢＭＹＨ１１分开统计，可 能 有不同 的 结 果，因 此 需 后 续 更 多 的 研 究［１０］。关 于 ＫＭＴ２Ａ（ＭＬＬ）基 因 重 排，在 ＡＭＬ 只 有 ＭＬＬＴ３ ＫＭＴ２Ａ／ｔ（９；１１）有详细研究［４］，结果显示诱导缓解 后 ＲＴｑＰＣＲ ＜１０－３和后续监测仍 ＜１０－３复发率低。 ＢＣＲＡＢＬ融合基因在 ＡＭＬ发生率低，用于 ＭＲＤ监 测的意义尚未有足够的临床验证 。 ［１１］ 以上研究结 果提示在用融合基因检测 ＭＲＤ方面，连续监测的 重要性，治疗结束后仍低度阳性不影响预后。 ２２ 突变基因 不是所有与 ＡＭＬ相关的突变基因 都适用于 ＭＲＤ监 测 。 ［１，４５，１０１１］ 造 血 干 细 胞 基 因 突 变后，获得竞争优势导致克隆造血，但仍有多系分化 和成熟的造血功能不属于白血病细胞，只有在继发 其他突变后才出现分化阻滞和无限增殖，发展为白 血病。随年龄增长干细胞的突变率增加，因此克隆 造血主要见于老年人，儿童少见。较常见的克隆造 血突变基因是编码表观遗传修饰因子的基因 ＤＮＭＴ３Ａ、ＴＥＴ２、ＩＤＨ、ＡＳＸＬ１，以 及 ＲＮＡ 剪 接 子 和 Ｃｏｈｅｓｉｎｓ蛋 白 的 基 因 等。胚 系 突 变 基 因 ＲＵＮＸ１、 ＧＡＴＡ２、ＣＥＢＰＡ、ＤＤＸ４１和 ＡＮＫＲＤ２６也 不 适 用 于 ＭＲＤ检测。与治疗前比较，缓解后突变基因的表达 水平仍没有明显下降，需考虑是克隆造血突变或胚 系突变基因。胚系突变基因可通过检测胚系组织 ／ 细胞（例如口腔黏膜等）ＤＮＡ发现。
益生菌对阿尔茨海默病作用的研究进展
益生菌对阿尔茨海默病作用的研究进展发布时间：2021-12-14T06:08:15.523Z 来源：《中国结合医学杂志》2021年12期作者：宋鑫萍1,2，李盛钰2，金清1[导读] 阿尔茨海默病已成为威胁全球老年人生命健康的主要疾病之一，患者数量逐年攀升，其护理的经济成本高，给全球经济造成重大挑战。
近年来研究显示，益生菌在适量使用时作为有益于宿主健康的微生物，在防治阿尔茨海默病方面具有积极影响，其作用机制可能通过调节肠道菌群，影响神经免疫系统，调控神经活性物质以及代谢产物，通过肠-脑轴影响该病发生和发展。
宋鑫萍1,2，李盛钰2，金清11.延边大学农学院，吉林延吉 1330022.吉林省农业科学院农产品加工研究所，吉林长春 130033摘要：阿尔茨海默病已成为威胁全球老年人生命健康的主要疾病之一，患者数量逐年攀升，其护理的经济成本高，给全球经济造成重大挑战。
近年来研究显示，益生菌在适量使用时作为有益于宿主健康的微生物，在防治阿尔茨海默病方面具有积极影响，其作用机制可能通过调节肠道菌群，影响神经免疫系统，调控神经活性物质以及代谢产物，通过肠-脑轴影响该病发生和发展。
本文综述了近几年来国内外益生菌对阿尔茨海默病的作用进展，以及其预防和治疗阿尔茨海默病的潜在作用机制。
关键词：益生菌；阿尔茨海默病；肠道菌群；机制Recent Progress in Research on Probiotics Effect on Alzheimer’s DiseaseSONG Xinping1,2，LI Shengyu2，JI Qing1*(1.College of Agricultural, Yanbian University, Yanji 133002，China)(2.Institute of Agro-food Technology, Jilin Academy of Agricultural Sciences, Chanchun 130033, China)Abstract：Alzheimer’s disease has become one of the major diseases threatening the life and health of the global elderly. The number of patients is increasing year by year, and the economic cost of nursing is high, which poses a major challenge to the global economy. In recent years, studies have shown that probiotics, as microorganisms beneficial to the health of the host, have a positive impact on the prevention and treatment of Alzheimer’s disease. Its mechanism may be through regulating intestinal flora, affecting the nervous immune system, regulating the neuroactive substances and metabolites, and affecting the occurrence and development of the disease through thegut- brain axis. This paper reviews the progress of probiotics on Alzheimer’s disease at home and abroad in recent years, as well as its potential mechanism of prevention and treatment.Key words：probiotics; Alzheimer’s disease; gut microbiota; mechanism阿尔茨海默病（Alzheimer’s disease, AD），系中枢神经系统退行性疾病，属于老年期痴呆常见类型，临床特征主要包括：记忆力减退、认知功能障碍、行为改变、焦虑和抑郁等。
Keap1
非小细胞肺癌(non-small cell lung cancer，NSCLC)发病率占据肺癌的75%~80%。
肿瘤细胞进展快且易扩散转移，临床常采用手术、放化疗等进行治疗，但5年生存率低于60%[1-2]。
氧化应激是由活性氧(ROS)生成量增加所致，ROS积累可诱导肺癌细胞凋亡，清除ROS 可阻止癌细胞凋亡，即肺癌细胞存活依赖于癌细胞自身抗氧化能力[3]。
Kelch样环氧氯丙烷相关蛋白-1 (kelch-like epichlorohydrin-associated protein-1，Keap1)/核因子E2相关因子2(nuclear factor E2related factor 2，Nrf2)信号通路在癌症中发挥重要调控作用，氧化应激可激活Keap1，促使Keap1-Nrf2复合物裂解，Nrf2转移至细胞核内，可激活下游靶基因表达，参与肺癌发生发展过程[4]。
Nrf2可维持氧化还原稳态，ROS侵袭细胞时，Nrf2可进入细胞核，结合抗氧化反应元件(ARE)转录编码各种抗氧化蛋白、代谢酶基因，抑制氧化应激反应[5-6]。
目前氧化应激、Keap1/Nrf2信号通路在NSCLC发生过程中的机制尚未明确。
基于此，本研究尝试分析Keap1/Nrf2信号通路与临床病理参数、氧化应激指标的相关性，探讨其在NSCLC氧化应激机制中的作用，为临床研制新药提供参考依据。
1资料与方法1.1一般资料选取2017年4月至2020年4月郑州市第三人民医院收治的100例NSCLC患者为研究对象。
纳入标准：符合NSCLC诊断标准[7]；术前未接受放化疗、免疫治疗者；预计生存期≥6个月；符合手术适应证、禁忌证；Karnofsky功能状态评分≥70分；签署知情同意书。
排除标准：合并凝血功能障碍、肝肾功能障碍、其他恶性肿瘤者；伴有急/慢性感染者；伴有精神疾病者；既往腹部相关外科手术史者。
所有患者均行肺癌根治性切除术，术中收集癌组织、癌旁组织(距离癌组织5cm范围内正常组织)，其中男性63例，女性37例；年龄46~67岁，平均(56.32±3.16)岁；体质量指数(BMI)17~30kg/m2，平均(23.16±2.03)kg/m2；病理类型：鳞癌58例、腺癌42例；病理分级[8]：Ⅰ~Ⅱ级51例、Ⅲ级49例；T分期[9]：T1~T253例、T3~T447例；N分期：N055例、N1~N245例。
肺泡灌洗液生物标志物的研究进展
肺泡灌洗液生物标志物的研究进展肺泡灌洗液是一种获取肺部疾病诊断和治疗信息的非常重要的方法。
在进行肺泡灌洗液的时候，医生会通过导管将溶液注入患者的肺部，然后通过抽取肺泡灌洗液来进行分析，以便于找到病原体或者其他异常。
近年来，一些生物标志物的研究越来越受到关注，它们可以为肺部疾病的诊断和治疗提供更加准确的信息。
本文将为您介绍肺泡灌洗液生物标志物的研究进展。
1、IL-6IL-6是一种细胞因子，它在机体免疫应答中起到重要作用。
近年来的研究发现，IL-6的水平可以作为肺部疾病的一个生物标志物，特别是在支气管哮喘和慢性阻塞性肺病等疾病的诊断和治疗中具有很高的价值。
2、TNF-αTNF-α是一种细胞因子，它可以刺激炎症反应并促进肿瘤坏死因子的释放。
在一些肺部疾病中，TNF-α的水平可以反映炎症程度，并且可以用来评估预后和治疗的疗效。
3、ECPECP是嗜酸粒细胞在抗病原体反应过程中释放的一种蛋白酶。
在肺部疾病中，ECP的水平可以作为反应病变和炎症严重程度的标志物，特别是在哮喘和气管炎等疾病中。
4、NENE是一种细胞膜上的酶，它在支气管肺泡灌洗液中的浓度可以作为肺部疾病的生物标志物，尤其是在气道炎症和哮喘的诊断和治疗中。
5、IDOIDO是调节免疫反应的一种酶，它可以降低T细胞的活性和浓度。
在肺部疾病的研究中，IDO的水平可以反映免疫系统的活性和炎症程度，以及预测疾病进展和疗效。
6、TGF-βTGF-β是一种细胞因子，它可以抑制炎症和免疫反应，并促进细胞增殖和分化。
在一些肺部疾病中，TGF-β的水平可以反映疾病的严重程度和预后，对于评估治疗效果和疾病进展也具有很高的价值。
综上所述，肺泡灌洗液生物标志物的研究已经取得了很大的进展，这些标志物可以为肺部疾病的诊断和治疗提供更加准确和有效的信息。
未来，随着技术的不断发展和研究的深入，我们可以预见，肺泡灌洗液生物标志物的应用将会更加广泛和深入。
香附的化学成分及其体外抗炎活性研究
香附的化学成分及其体外抗炎活性研究韩建卫;孙延平;杨炳友;王秋红;匡海学【期刊名称】《中南药学》【年(卷),期】2024(22)2【摘要】目的研究香附Cyperi Rhizoma的化学成分及其抗炎活性。
方法利用硅胶、Sephadex LH-20和制备型正相HPLC对香附95%乙醇提取物进行分离纯化,根据理化性质及波谱数据鉴定所得化合物的结构。
以脂多糖诱导的小鼠小胶质细胞BV-2炎症模型评价其抗炎活性。
结果从香附中分离得到15个化合物,鉴定为:24-methylenecycloartenone(1)、cyperenal(2)、patchoulenone(3)、4,5,6,7,8,8a-六氢-3,4,8,8-四甲基-1H-3a,7-亚甲基甘菊环-4-醇甲酸酯(4)、4-烯-广藿香醇(5)、cyperenol(6)、cyperolactone(7)、(-)-caryophyllene oxide(8)、humulene epoxideⅡ(9)、humulene diepoxide A(10)、α-tocopherol(11)、litseachromolaevane A(12)、hyperhubein G(13)、nootkatone(14)和mustakone(15)。
化合物4和11可显著抑制NO的释放,抑制率分别为(49.17±0.01)%和(51.91±0.05)%。
结论本文首次使用制备型正相HPLC技术对香附石油醚层进行系统分离,化合物2、6、9~11和13为首次从莎草科植物中分离得到,化合物12为首次从莎草属植物中分离得到,化合物4、5和7为首次从香附中分离得到。
化合物4和11有较强的体外抗炎活性。
【总页数】7页(P322-328)【作者】韩建卫;孙延平;杨炳友;王秋红;匡海学【作者单位】黑龙江中医药大学;广东药科大学中药学院【正文语种】中文【中图分类】R284.1【相关文献】1.香附黄酮的体外抗氧化活性研究2.白菊木树皮和枝叶甲醇提取物及化学成分的体外抗炎活性研究3.长叶纽子果根醇提物乙酸乙酯萃取部位的化学成分及体外抗炎活性研究4.苦皮藤根化学成分及其提取物体外抗炎活性研究5.大黄鲜切过程对化学成分、泻下、抗炎及体外抗氧化活性的影响因版权原因，仅展示原文概要，查看原文内容请购买。